U.S. Markets open in 4 hrs 14 mins

Castle Biosciences, Inc. (CSTL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
72.59+0.73 (+1.02%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close71.86
Open71.52
Bid68.00 x 900
Ask0.00 x 1000
Day's Range70.71 - 73.13
52 Week Range34.72 - 107.69
Volume217,716
Avg. Volume277,300
Market Cap1.819B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.21
Earnings DateMay 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est86.83
  • Castle Biosciences Announces Receipt of New York Laboratory Permit
    Business Wire

    Castle Biosciences Announces Receipt of New York Laboratory Permit

    Castle announced that it has received approval from the New York State Department of Health for its DecisionDx-SCC test.

  • Business Wire

    Castle Biosciences to Participate at the Baird 2021 Healthcare ESG Symposium

    Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Baird 2021 Healthcare ESG Symposium on June 17, 2021, at 11:20 a.m. Eastern time.

  • AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors
    PR Newswire

    AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors

    AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ: CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful launch and commercialization of their diagnostic tests in uveal and cutaneous melanoma.